Yaya Chu , Aliza Gardenswartz , Caroline Diorio , Lianna J. Marks , Eric Lowe , David T. Teachey , Mitchell S. Cairo
{"title":"非霍奇金淋巴瘤儿童、青少年和年轻人的细胞和体液免疫治疗","authors":"Yaya Chu , Aliza Gardenswartz , Caroline Diorio , Lianna J. Marks , Eric Lowe , David T. Teachey , Mitchell S. Cairo","doi":"10.1016/j.beha.2023.101442","DOIUrl":null,"url":null,"abstract":"<div><p>The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 1","pages":"Article 101442"},"PeriodicalIF":2.2000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma\",\"authors\":\"Yaya Chu , Aliza Gardenswartz , Caroline Diorio , Lianna J. Marks , Eric Lowe , David T. Teachey , Mitchell S. Cairo\",\"doi\":\"10.1016/j.beha.2023.101442\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.</p></div>\",\"PeriodicalId\":8744,\"journal\":{\"name\":\"Best Practice & Research Clinical Haematology\",\"volume\":\"36 1\",\"pages\":\"Article 101442\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research Clinical Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521692623000038\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692623000038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 2
摘要
儿童、青少年和年轻成人（CAYA）复发和/或难治性（R/R）非霍奇金淋巴瘤（NHL）的预后不佳（2年总生存率低于25%）。这种低风险人群迫切需要新的靶向疗法。CD19、CD20、CD22、CD79a、CD38、CD30、LMP1和LMP2是R/R NHL CAYA患者免疫治疗的有吸引力的靶点。新的抗CD20单克隆抗体、抗CD38单克隆抗体、抗体-药物偶联物以及T和自然杀伤（NK）细胞双特异性和三特异性结合物正在R/R环境中进行研究，并正在改变NHL治疗的前景。已经研究了多种细胞免疫疗法，如病毒活化的细胞毒性T淋巴细胞、嵌合抗原受体（CAR）T细胞、NK和CAR NK细胞，并为患有R/R NHL的CAYA患者提供了替代选择。在这里，我们提供了在患有R/R NHL的CAYA患者中利用这些细胞和体液免疫疗法的最新情况和临床实践指导。
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.
期刊介绍：
Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
